These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10758440)

  • 21. Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.
    Warriner CB; Knox D; Belo S; Cole C; Finegan BA; Perreault L
    Can J Anaesth; 1997 Nov; 44(11):1167-73. PubMed ID: 9398956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dolasetron decreases postoperative nausea and vomiting after breast surgery.
    Abou Zeid H; Al-Gahamdi A; Abdul-Hadi M
    Breast J; 2002; 8(4):216-21. PubMed ID: 12100113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dolasetron for the prevention of postoperative vomiting in children undergoing strabismus surgery.
    Wagner D; Pandit U; Voepel-Lewis T; Weber M
    Paediatr Anaesth; 2003 Jul; 13(6):522-6. PubMed ID: 12846709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group.
    Kovac A; Mingus M; Sung YF; Neary M
    J Clin Anesth; 1999 May; 11(3):235-41. PubMed ID: 10434221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
    Yeilding A; Bertoli L; Eisenberg P; Plezia P; Modiano MR; Alberts DS; Khojasteh A; Cramer MB; Hahne WF
    Am J Clin Oncol; 1996 Dec; 19(6):619-23. PubMed ID: 8931684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention of postoperative nausea and vomiting after hysterectomy with oral dolasetron, intravenous dehydrobenzperidol or a combination of both substances].
    Triem JG; Piper SN; Maleck WH; Schenck A; Schmidt CC; Boldt J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Jun; 34(6):340-4. PubMed ID: 10429771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis.
    Zarate E; Watcha MF; White PF; Klein KW; Sa Rego M; Stewart DG
    Anesth Analg; 2000 Jun; 90(6):1352-8. PubMed ID: 10825320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dolasetron versus ondansetron for the treatment of postoperative nausea and vomiting.
    Meyer TA; Roberson CR; Rajab MH; Davis J; McLeskey CH
    Anesth Analg; 2005 Feb; 100(2):373-377. PubMed ID: 15673860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placebo-controlled comparison of dolasetron and metoclopramide in preventing postoperative nausea and vomiting in patients undergoing hysterectomy.
    Piper SN; Triem JG; Maleck WH; Fent MT; Hüttner I; Boldt J
    Eur J Anaesthesiol; 2001 Apr; 18(4):251-6. PubMed ID: 11350463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dolasetron versus ondansetron as single-agent prophylaxis for patients at increased risk for postoperative nausea and vomiting: a prospective, double-blind, randomized trial.
    Birmingham SD; Mecklenburg BW; Lujan E; Dacanay RG; Boyle PK; Green R
    Mil Med; 2006 Sep; 171(9):913-6. PubMed ID: 17036618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind trial of dolasetron versus droperidol for prophylaxis of postoperative nausea and vomiting in patients undergoing TRAM flap breast reconstruction surgery.
    Loewen P; Lamb S; Clugston P
    Ann Plast Surg; 2003 Nov; 51(5):472-7. PubMed ID: 14595183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inspired oxygen fraction of 0.8 compared with 0.4 does not further reduce postoperative nausea and vomiting in dolasetron-treated patients undergoing laparoscopic cholecystectomy.
    Piper SN; Röhm KD; Boldt J; Faust KL; Maleck WH; Kranke P; Suttner SW
    Br J Anaesth; 2006 Nov; 97(5):647-53. PubMed ID: 16963789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ondansetron and dolasetron provide equivalent postoperative vomiting control after ambulatory tonsillectomy in dexamethasone-pretreated children.
    Sukhani R; Pappas AL; Lurie J; Hotaling AJ; Park A; Fluder E
    Anesth Analg; 2002 Nov; 95(5):1230-5, table of contents. PubMed ID: 12401599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
    Fortney JT; Gan TJ; Graczyk S; Wetchler B; Melson T; Khalil S; McKenzie R; Parrillo S; Glass PS; Moote C; Wermeling D; Parasuraman TV; Duncan B; Creed MR
    Anesth Analg; 1998 Apr; 86(4):731-8. PubMed ID: 9539593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolasetron, but not metoclopramide prevents nausea and vomiting in patients undergoing laparoscopic cholecystectomy.
    Piper SN; Suttner SW; Röhm KD; Maleck WH; Larbig E; Boldt J
    Can J Anaesth; 2002 Dec; 49(10):1021-8. PubMed ID: 12477671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
    Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
    Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.